Drugs / Atumelnant
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07570082 | May → Dec 2026 expected | — | Crinetics Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 1 | NCT07221084 | Oct 2025 → Feb 2026 | — | Crinetics Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1 | NCT06048887 | Dec 2020 → Apr 2022 | — | Crinetics Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05804669 | Oct 2023 → Oct 2026 expected | ACTH-dependent Cushing syndrome, ectopic ACTH secretion syndrome | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06712823 | Feb 2025 → Jul 2029 expected | classic congenital adrenal hyperplasia | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 2 | NCT05907291 | Jul 2023 → Aug 2025 | classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency | Crinetics Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07159841 | Jan 2026 → Mar 2030 expected | classic congenital adrenal hyperplasia | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT07144163 | Dec 2025 → May 2027 expected | classic congenital adrenal hyperplasia | Crinetics Pharmaceuticals Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-06-14 | Crinetics Pharmaceuticals Inc. | Results Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Presentation at ENDO 2026 crinetics.com ↗
Data show investigational atumelnant drove sustained androgen reductions while enabling lowering of glucocorticoid supplementation to physiologically normal levels in adults with classic CAH |
| 2026-01-05 | Crinetics Pharmaceuticals Inc. | Results Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and Glucocorticoid Dose Reduction in Phase 2 Trial of Atumelnant for Congenital Adrenal Hyperplasia crinetics.com ↗
Crinetics also announced positive topline results from the fourth cohort of its Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. |
| 2025-08-21 | Crinetics Pharmaceuticals Inc. | Regulatory Crinetics Receives FDA Orphan Drug Designation for Atumelnant in the Treatment of Congenital Adrenal Hyperplasia (CAH) crinetics.com ↗
today announced that the U.S. Food and Drug Administration (FDA) granted Orphan Drug Designation (ODD) for atumelnant |
| 2025-01-10 | Crinetics Pharmaceuticals Inc. | Results Crinetics Announces Positive Topline Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) crinetics.com ↗
Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced positive topline results from an open-label, Phase 2 congenital adrenal hyperplasia (CAH) study of investigational atumelnant, a novel, once-daily oral adrenocorticotropic hormone (ACTH) receptor antagonist candidate being developed for the treatment of classic CAH and ACTH-dependent Cushing’s syndrome. |
| 2024-06-03 | Crinetics Pharmaceuticals Inc. | Results Crinetics Announces Positive Initial Findings at ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing’s Syndrome (ADCS) crinetics.com ↗
In all participants, 24h urine free cortisol was below the upper limit of normal during the treatment period even while receiving oral hydrocortisone replacement. |
| 2022-05-25 | Crinetics Pharmaceuticals Inc. | Results Crinetics Reports Top-line CRN04894 MAD Results from Phase 1 Study crinetics.com ↗
Following administration of CRN04894 , results showed serum cortisol below normal levels and a marked reduction in 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations. |
| 2021-08-10 | Crinetics Pharmaceuticals Inc. | Results CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-Dependent Cortisol Suppression in Phase 1 Single Ascending Dose Study crinetics.com ↗ |
| 2021-08-10 | Crinetics Pharmaceuticals Inc. | Results Crinetics’ Second Quarter 2021 Financial Results and Corporate Update crinetics.com ↗
This program continues to follow the blueprint of paltusotine’s success, as early clinical data have provided proof-of-concept by demonstrating the dose-dependent and clinically-significant pharmacodynamic effects of CRN04894 on a well validated hormonal biomarker. |
All press releases naming this drug 15 releases
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | atumelnant | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05804669 ↗ |
| Known as | CRN04894 | “The purpose of this study is to evaluate the long-term safety, tolerability, and efficacy of atumelnant (CRN04894).” NCT06712823 ↗3“associated with atumelnant (also known as CRN04894)” NCT05804669 ↗ “atumelnant (CRN04894)” NCT05907291 ↗ |
| Action | Inhibit | “antagonizes the action of ACTH at its receptor” NCT05804669 ↗ |
| Modality | Small molecule | “Atumelnant is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.” NCT05907291 ↗ |
| Route | Oral | “administered as oral tablets” NCT05804669 ↗ |
| Target | MC2R | “CRN04894 is an orally active nonpeptide melanocortin 2 receptor (MC2R) or adrenocorticotropic hormone (ACTH) antagonist.” NCT06048887 ↗ |